Vulnerable Patient Meeting

A Cardialysis Event

18th 20th JUNE 2017

PROGRAM

GREECE CRETE HERAKLION ATLANTIS HOTEL





OUTLINE

DAY 1

Basics

- Sudden Death and Vulnerable Patient
- Vulnerable plaque I: from biomarkers to biological mechanisms
- Vulnerable plaque II: from biomarkers to biological mechanisms
- **⑤** Vulnerable plaque morphology: new insights
- Pre-clinical Molecular Targeting

DAY 2

Mechanisms and Imaging

- Intravascular Imaging
- TECHNICAL CORNER: Emerging intravascular imaging in preclinical phase
- Big Data Approaches to Identify Vulnerable Patients/ Plaques in the Cath Lab
- Biomechanical modeling
- Clinical I
- Clinical II
- Making the fantasy into reality? Commercial developments

DAY 3

Treatment

- Non-invasive imaging for detection of vulnerable plaque
- Therapeutic approach to Vulnerable Plaque
- Trial Corner I Plaque imaging studies
- Trial corner II Clinical studies assessing the efficacy of emerging therapies in preventing atherosclerotic evolution and local therapy
- Final Debate



Welcome remarks

08:00



	guest director Prof. Panos Vardas
08.10	Sudden death and vulnerable patient Chairmen: Panos Vardas and Patrick W. Serruys
08:10	What do we know about sudden death? Presentation of vulnerable patient Vasim Farooq (UK)
08:23	Sudden cardiac death: rupture of vulnerable plaque without preceding episode and pathophysiology of acute ischemia related arrhythmia Panos Vardas (GR)
08:36	Extrinsic factors related to sudden coronary death and myocardial infarction with emphasis on cigarette smoking John Ambrose (USA)
08:49	Impact of intravenous DAPT on outcomes in comatose patients after acute myocardial infarction Vasim Farooq (UK)
09:02	New approach to phenotyping patients at risk of sudden death by MRI imaging Ranil De Silva (UK)
09:15	Discussion
09:35	Vulnerable time: ECG monitoring to shorten a symptom-to- balloon time Amir Lerman (USA)
09:48	Cooling and bioresorption of thieropyridine after myocardial infarction Marko Noč (SL)
10:01	Futuristic view on management/treatment of patient at risk of sudden death Panos Vardas (GR)



Discussion

10:11



10:56	Vulnerable Plaque I: from biomarkers to biological mechanisms Chairmen: Ranil De Silva and Wolfgang Koenig
10:56	Immunoglobulin as a risk predictors in coronary heart disease Ramzi Khamis (UK)
11:09	Oxidative stress and cardiovascular events Riyaz Patel (UK)
11:22	Association between diet and the stability of human coronary plaque as studied with radio-decay Isabel Gonçalves (UK)
11:35	Transcriptional control of vascular stability Anna Randi (UK)
11:48	Discussion
12:08	Lunch
13:38	Vulnerable Plaque II: from biomarkers to biological mechanisms Chairmen: Ranil De Silva and Wolfgang Koenig
13:38	Inflammatory transcriptional networks in endothelial cells and plaque vulnerability Rob Krams (UK)
13:51	Ageing and the biology of atherosclerosis Martin Bennett (UK)
14:04	Vulnerable microcirculation Javier Escaned (SP)
14:17	Uric acid: is it of any relevance to cardiologists? Dorian Haskard (UK)
14:40	Coronary plaque angiogenesis: new insights Michael Joner (DE)
14:53	Discussion
15:13	Break

DAY 1 SUNDAY JUNE 18, 2017



18:07 Adjourn

15:43	Vulnerable plaque morphology: new insights Chairmen: Dorian Haskard and Wolfgang Koenig
15:43	Sphingolipids as novel targets of plaque inflammation Isabel Gonçalves (UK)
15:56	Vasospasm and plaque instability Takashi Akasaka (JP)
16:09	MRI plaque characterisation Michelle Williams (UK)
16:22	18F-sodium fluoride positron emission tomography Michelle Williams (UK)
16:35	Discussion
16:55	Pre-clinical Molecular Targeting Chairmen: Jim Muller and Christos Bourantas
16:55 16:55	
	Chairmen: Jim Muller and Christos Bourantas Molecular targeting of oxidized LDL in coronary atherosclerosis
16:55	Chairmen: Jim Muller and Christos Bourantas Molecular targeting of oxidized LDL in coronary atherosclerosis Ramzi Khamis (UK) Nanoparticles for molecular targeting
16:55 17:08	Chairmen: Jim Muller and Christos Bourantas Molecular targeting of oxidized LDL in coronary atherosclerosis Ramzi Khamis (UK) Nanoparticles for molecular targeting Rob Krams (UK) Collagen-4 targeting nanoparticles



10:02

Break

08:00	Intravascular Imaging Chairmen: Jim Muller and Chris Bourantas
08:00	Introduction Jim Muller (USA)
08:05	Introduction of OCT atlas for detecting vulnerable plaque Yoshinobu Onuma (NL)
08:15	Strength and Weakness of IVUS in detecting vulnerable plaques: A critical appraisal Akiko Maehara (USA)
08:25	Strength and weakness of IVUS-NIRS in detecting vulnerable plaques: a critical appraisal David Erlinge (SE)
08:35	Discussion
08:50	TECHNICAL CORNER: Emerging intravascular imaging in preclinical phase Chairmen: Ton van der Steen and Christos Bourantas
08:50	Ultra-high speed ECG triggered OCT Jin Won Kim (KR)
08:57	IVUS-OCT - Terumo Yoshinobu Onuma (NL)
09:04	NIRF-IVUS/-OCT-NIRAF OCT-NIRF Farouc Jaffer (USA)
09:11	IVUS-TRFS Laura Marcu (USA)
09:18	IVUS-IVPA Ton van der Steen (NL)
09:25	Other commercially available technologies Akiko Maehara (USA)
09.32	Discussion Clinical value and future application of the existing intravascular imaging

DAY 2 MONDAY JUNE 19, 2017



12:49

Lunch

7

10:32	Big data approaches to identify vulnerable patients/plaques in the cath lab Chairmen: Wolfgang Koenig and Ranil de Silva
10:32	Can neural networks enable virtual histology IVOCT? Vik Baruah (USA)
10:45	Leveraging machine learning techniques to forecast patient prognosis after percutaneous coronary intervention Amir Lerman (USA)
10:58	Machine learning to identify biomechanical signatures of advanced coronary plaque formation Ranil de Silva (UK)
11:11	Discussion
11:26	Biomechanical modeling Chairmen: Jolanda Wentzel and Rob Krams
11:26	Keynote lecture: summary of shear stress meeting in Rotterdam on April 4-5, 2017 Jolanda Wentzel (NL)
11:49	Fluid shear stress and mechanotransduction in vascular health and disease Paul Evans (UK)
11:59	Progression imaging and shear stress using micro-CT in preclinical models Kim van der Heiden (NL)
12:09	Fluid structure interaction modelling of coronary plaque – from mouse to man Rob Krams (UK)
12:19	Combined non-invasive assessment of endothelial shear stress and molecular imaging of inflammation for the prediction of inflamed plaque in hyperlipidaemic rabbit aortas Gitsios Gitsioudis (DE)
12:29	Panel discussion: Lessons learnt from preclinical modelling which parameter should be measured for predicting i) plaque progression, or ii) plaque vulnerability?



14:19	Clinical I Chairmen: Jim Muller and Ton van der Steen
14:19	Development and validation of OCT software for light property analysis Yoshinobu Onuma (NL)
14:32	Shear stress and plaque development – update of preclinical and clinical studies from Rotterdam experience Jolanda Wenzel (NL)
14:45	Coronary artery axial plaque stress and its relationship with plaque rupture and clinical presentation Charles Taylor (USA)
14:58	Which is better or worse - high or low shear stress? Insights from analysis of culprit of PROSPECT Peter Stone (USA)
15:11	Solid wall mechanics for prediction of future events - insights from PROSPECT Martin Bennett (UK)
15:24	Discussion
15:39	Break
15:39	Clinical II Chairmen: Jim Muller and Ton van der Steen
	Clinical II
16:09	Clinical II Chairmen: Jim Muller and Ton van der Steen Is high shear stress a physiologic marker of plaque vulnerability?
16:09	Clinical II Chairmen: Jim Muller and Ton van der Steen Is high shear stress a physiologic marker of plaque vulnerability? Habib Samady (USA) Does functional assessment of epicardial coronary artery stenosis severity predict future coronary events? If so, why?
16:09 16:22	Clinical II Chairmen: Jim Muller and Ton van der Steen Is high shear stress a physiologic marker of plaque vulnerability? Habib Samady (USA) Does functional assessment of epicardial coronary artery stenosis severity predict future coronary events? If so, why? Javier Escaned (SP) Shear stress analysis in multi-modality imaging: a subanalysis of the IBIS 4 study

DAY 2 MONDAY JUNE 19, 2017



9

17:21	Making the fantasy into reality? Commercial developments Chairmen: Patrick Serruys and Yoshinobu Onuma
17:21	PIE medical: angiogram derived FFR and shear stress Jean Paul Aben (NL)
17:34	MEDIS: application of CE-marked QFR software in a clinical trial assessing the efficacy of coronary stents Patrick Serruys (UK)
17:47	HeartFlow Charles Taylor (USA)
18:00	Discussion

18:15 Adjourn

Tuesday June 20, 2017 10

11:08

Break

08:15	Non-invasive imaging for detection of vulnerable plaque Chairmen: Christos Bourantas and Jim Muller
08:15	Ultrafast contrast enhanced ultrasound for improved cardiovascular Meng-Xing Tang (UK)
08:28	MSCT beyond lumen assessment in clinical setting: plaque composition, syntax score and functional assessment Carlos Collet (VE)
08:44	MSCT for detecting vulnerable plaque: biomarker and imaging correlation Daniele Andreini (IT)
08:57	Discussion
09:12	Therapeutic approach to vulnerable plaque Chairmen: Patrick W. Serruys and Gregg Stone
09:12	Genotype and clinical outcomes dalGenE trial Wolfgang Koenig (DE)
09:25	ABSORB II: glagovian appraisal of vessel remodelling Patrick Serruys (UK)
09:38	PROSPECT II, ABSORB and PREVENT Gregg Stone (USA)
09:51	GLAGOV and FOURIER Giovas Periklis (CH)
10:04	Panel discussion: Will imaging regain a central role in early clinical development?
10:22	ORION-1: inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol Wolfgang Koenig (DE)
10:35	Is the PCSK-9 treatment cost effective in the european health system? Panos Vardas (GR)
10:48	Discussion

DAY 3 TUESDAY JUNE 20 2017



15:49

16:09

precision medicine

Adjourn

11

11:38	Trial corner I – plaque imaging studies Chairmen: Gregg Stone and Amir Lerman
11:38	Lipid rich plaque trial (design/potential strength and weakness of the trial) Jim Muller (USA)
11:51	IBIS-3 antibodies Ramzi Khamis (UK)
12:04	IBIS-4 Lorenz Räber (CH)
12:17	Atheroremo (FP7 Project) Wolfgang Koenig (DE)
12:30	Discussion
12:50	Lunch
14:50	Trial corner II - Clinical studies assessing the efficacy of emerging therapies in preventing atherosclerotic evolution and local therapy Chairmen: Gregg Stone and Amir Lerman
14:50 14:50	emerging therapies in preventing atherosclerotic evolution and local therapy
	emerging therapies in preventing atherosclerotic evolution and local therapy Chairmen: Gregg Stone and Amir Lerman CIRT / CANTOS
14:50	emerging therapies in preventing atherosclerotic evolution and local therapy Chairmen: Gregg Stone and Amir Lerman CIRT / CANTOS Wolfgang Koenig (DE) HDL remodelling by CSL112 / AEGIS-1
14:50 15:03	emerging therapies in preventing atherosclerotic evolution and local therapy Chairmen: Gregg Stone and Amir Lerman CIRT / CANTOS Wolfgang Koenig (DE) HDL remodelling by CSL112 / AEGIS-1 Samuel Wright (USA) Stent-based gene delivery

Panel discussion: Diagnosis and therapy of vulnerable plaque for





GENERAL INFORMATION

DATES & PLACE The Meeting will be held June 18, 19 and 20, 2017, at the Aquila Altantis Hotel, in Heraklion Crete.

Heraklion is the largest city and port of Crete, has a history of many centuries, a history that gave to the city a unique character and an unmatched charm. A charm to be discovered at every step of yours, from the old Venetian town to the modern European capital. Heraklion is one of the Greek cities with the longer history. Here was developed the Minoan civilization. Heraklion is a mosaic of civilizations, an alloy of Arabic, Byzantine and Venetian influences!

VENUE AQUILA ATLANTIS HOTEL, HERAKLION

2, Ygeias Str, Heraklion, Crete, GR - 71 202

Tel: +30 2810 229 103 | Fax: +30 2810 226 265 | www.aquilahotels.com

The Aguila Atlantis Hotel is located in the centre of Heraklion.

SCIENTIFIC PRESENTATIONS The Meeting room will be equipped with Screen, Data Video Projector for Microsoft Power Point presentations, Note pads, pens and laser pointers.

Please download your presentation at the meeting secretariat in advance (preferably the day before).

TRANSFER SERVICES FROM/ TO AIRPORT Transfer services will be available to/from Heraklion airport according to your flight itinerary.

Kindly note, that there will be a transfer service arranged for you upon your arrival and departure. Pick-up time for your departure transfer will be 2hrs and 30mns prior your flight departure.

SPECIAL THANKS TO





























MEETING SECRETARIAT & OFFICIAL TRAVEL AGENCY

The Meeting's Secretariat will operate during meeting hours.



ERA Ltd. 17 Asklipiou Str., 106 80, Athens, Greece

T.: +30 210 3634944 | F.: + 30 210 3631690 | E.: info@era.gr | W.: www.era.gr